Efficacy and Safety of Sacubitril/Valsartan in HFrEF Patients with Low SBP: Insights from PARADIGM-HF
The present analysis evaluated the efficacy and safety of sacubitril/over enalapril in HF patients across different levels of SBP.
The present study is a critical appraisal of the existing evidence on the benefits and harms of sacubitril/valsartan in patients with HFrEF.
As per the study sacubitril/valsartan causes greater reduction in HbA1c vs. enalapril and cuts new insulin initiation in diabetes patients with...
This study shows that azilsartan can be the preferred ARB in hypertensives with prediabetes or type 2 diabetes